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OBJECTIVES We sought to assess the mechanism and prognostic value of elevated troponins in patients
without acute coronary syndromes (ACS).
BACKGROUND Cardiac troponins are used as specific markers for the diagnosis of ACS. Recent studies
reported a considerable number of critically ill patients without ACS as being troponin-
positive, especially patients with sepsis, pulmonary embolism, renal failure, and stroke.
METHODS We analyzed 58 consecutive, critically ill patients admitted for reasons other than ACS,
according to their troponin status. Thirty-day mortality, left ventricular ejection fraction
(LVEF), and a panel of inflammatory cytokines were compared between troponin-positive
and troponin-negative patients. Relevant coronary artery disease was excluded either by stress
echocardiography or autopsy.
RESULTS Of the 58 critically ill patients, 32 (55%) without evidence of ACS were troponin-positive.
Positive troponin levels were associated with higher mortality (22.4% vs. 5.2%, p  0.018)
and a lower LVEF (p  0.0006). Troponin-positive patients had significantly higher median
levels of tumor necrosis factor (TNF)-alpha, its soluble receptor, and interleukin (IL)-6. A
subgroup of 10 aplastic patients was troponin-negative at study entry. Three became
troponin-positive during leukocyte recovery and subsequently died, whereas all the others
stayed troponin-negative and survived. Flow-limiting coronary artery disease was not
demonstrable at autopsy or stress echocardiography in 72% of troponin-positive patients.
CONCLUSIONS Elevated troponin is a mortality risk factor for medical intensive care patients admitted for
reasons other than ACS. It is associated with decreased left ventricular function and higher
levels of TNF-alpha and IL-6. (J Am Coll Cardiol 2003;41:2004–9) © 2003 by the
American College of Cardiology Foundation
Cardiac isoforms of troponin I (cTnI) and troponin T
(cTnT) are highly sensitive and specific markers of myocar-
dial injury. The measurement of cTnI and cTnT in blood
has recently been accepted by the Joint Committee of the
European Society of Cardiology and the American College
of Cardiology as the standard biomarker for the diagnosis of
acute myocardial infarction and by the American College of
Cardiology and the American Heart Association for the
diagnosis and management of unstable angina (1,2). In the
setting of an acute coronary syndrome (ACS), cardiac
troponins identify patients with a several-fold increased risk
of death in the subsequent weeks (3). Besides this enthusi-
asm for troponin measurements in ACS, there have been
several reports demonstrating a high incidence of elevated
troponin levels in patients with sepsis and septic shock
(4–9). In contrast to the extensive literature on troponins in
ACS, which suggests that abnormal concentrations of
cardiac troponins always represent irreversible myocardial
damage, there is evidence that cardiac troponins might be
released by other mechanisms, such as reversible myocardial
ischemia (10). This fits the observation that myocardial
depression during sepsis is a fully reversible process in
patients surviving sepsis (11). Cardiac troponins have also
been reported to predict mortality in early sepsis, end-stage
renal disease, acute stroke, and pulmonary embolism (5,12–
14). Therefore, it is of great interest to understand the
underlying mechanisms leading to elevated cardiac tro-
ponins, besides ACS. Hence, the aim of this study was to
investigate the mechanism of elevated cardiac troponins in
patients admitted to the intensive care unit and understand
their impact for predicting mortality in patients without
ACS.
METHODS
Study population. Fifty-eight critically ill patients referred
to two medical intensive care units for sepsis, septic shock,
systemic inflammatory response syndrome, and other severe
diseases, except ACS, myocardial infarction, or recent
cardiac surgery, were consecutively included within 24 h
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after admittance. Definitions of sepsis, septic shock, and
systemic inflammatory response syndrome (SIRS) corre-
sponded to the criteria of the consensus conference (15). In
short, SIRS is defined as a systemic inflammatory response
to a variety of clinical insults. The response is manifested by
two or more of the following conditions: temperature
38°C or 36°C, heart rate 90 beats/min, respiratory
rate 20 breaths/min or PaCO2 32 mm Hg, and white
blood cell count 12,000/mm3 or 4,000/mm3. Sepsis is
defined as SIRS in response to proven infection. Septic
shock is defined as sepsis-induced hypotension, despite
adequate fluid resuscitation needing catecholamine support.
Patients presenting with chest pain and one additional
sign of acute coronary artery disease (dynamic ST-segment
elevation or depression 1 mm on the 12-lead electrocar-
diogram or creatine kinase levels twice the upper limit),
patients with recent cardiac surgery and those admitted to
the intensive care unit only for the purpose of observation
24 h were excluded. Because of these strictly applied
exclusion criteria, the majority of the study population in
our medical intensive care units consisted of patients with
severe infections, and only a minority suffered from other
diseases (Table 1). The local ethics committee of both
hospitals approved the study. All patients, or in case of
unconsciousness, their closest relative, signed a written,
informed consent.
Data collection. The Simplified Acute Physiology Score II
(SAPS-II) was used to analyze disease severity at study
entrance (16). The original reference provides a mathemat-
ical model to calculate mortality from SAPS-II. The ap-
proximate percentages are as follows (SAPS-II/mortality):
20 points/5%, 40 points/25%, 50 points/50%, 60 points/
70%, and 80 points/90%.
The left ventricular ejection fraction (LVEF) was as-
sessed by echocardiography, using the Simpson biplane
formula (17), within 24 h of study inclusion by a cardiologist
blinded to the troponin levels. Patient survival was assessed
30 days after study inclusion. In case of death, an autopsy
was performed. To exclude relevant coronary artery disease
in troponin-positive patients, dobutamine stress echocardi-
ography was performed according to standard procedures
(18) in survivors within three months after recovery. Anal-
ysis of stress echocardiograms was performed by two expe-
rienced cardiologists.
Laboratory diagnostics. Blood samples for determination
of cardiac troponins and cytokines were taken at the time of
study inclusion and after 3, 12, 24, 48, 96, and 192 h.
Analysis of cardiac troponins was performed from the serum
on a day-to-day basis, and samples for the determination of
cytokine levels were centrifuged immediately after the blood
was taken and frozen at 20°C. The cTnT levels were
assessed with the third-generation test (Elecsys) from
Roche Diagnostics (Rotkreuz, Switzerland), and cTnI levels
with a second-generation test using the AccessAnalyzer
(Beckman Coulter Inc., Fullerton, California). The cutoff
level was indicated as 0.1 g/l by the manufacturer for both
cTnI and cTnT and was predefined before starting the
study. Patients with at least two positive troponin measure-
ments (cTnI or cTnT) were called “troponin-positive.”
C-reactive protein measurement was done on an Integra
700 analyzer (Roche Diagnostics), and levels 5 mg/l were
considered positive.
Tumor necrosis factor (TNF)-alpha was assessed by an
enzyme-linked immunosorbent assay (ELISA) (Endogen,
Boston, Massachusetts; cutoff 6.3 pg/ml). For determina-
tion of TNF-alpha receptor, an ELISA from Bender
Med Systems (Vienna, Austria; cutoff 0.49 ng/ml) was
used. Analyses of interleukin (IL)-1-beta, IL-6, IL-8, and
soluble intercellular adhesion molecule-1 were performed
with ELISA (R&D Research and Diagnostics System,
Minneapolis, Minnesota). Cutoff levels were 0.1 pg/ml,
3.1 pg/ml, 0.1 pg/ml, and 300 ng/ml, respectively.
Statistical analysis. Continuous data are expressed as the
mean value  SD or as the median value with interquartile
range, as appropriate. The chi-square test was used to
Table 1. Baseline Characteristics of the Study Population
(n  58)
Age (yrs) 55  21
Female gender 30 (52%)
White race 53 (91%)
Body mass index (kg/m2) 25  5
SAPS-II (points) 42  15
Shock requiring supportive therapy with catecholamines 24 (41%)
Main diagnoses
SIRS/sepsis—immunocompetent 21 (36%)
SIRS/sepsis—aplastic 6 (11%)
Septic shock—immunocompetent 20 (34%)
Septic shock—aplastic 4 (7%)
Others* 7 (12%)
Troponin-positive measurement
cTnI or cTnT 32 (55%)
cTnI 28 (48%)
cTnT 27 (47%)
Type of infection
Bacterial, gram-positive 15 (26%)
Bacterial, gram-negative 19 (33%)
Mixed and others† 4 (7%)
Culture negative 20 (34%)
*The diagnoses of these patients were two intoxications, two severe gastrointestinal
bleedings, one anaphylactic shock, one pulmonary disease, and one diabetic ketoac-
idosis. †Two patients had mixed gram-positive and gram-negative bacterial infection,
one had systemic Candida, and one had systemic Epstein-Barr virus infection. Data
are presented as the mean value  SD or number (%) of patients.
cTnI or cTnT  cardiac troponin I or T, respectively; SAPS-II  Simplified
Acute Physiology Score II (higher scores indicate more severe illness); SIRS 
systemic inflammatory response syndrome.
Abbreviations and Acronyms
ACS  acute coronary syndromes
cTnI  cardiac troponin I
cTnT  cardiac troponin T
IL  interleukin
LVEF  left ventricular ejection fraction
SAPS  Simplified Acute Physiology Score
SIRS  systemic inflammatory response syndrome
TNF  tumor necrosis factor
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compare troponin-positive and -negative patients with re-
spect to “shock” and “no shock” status. The association
between LVEF and troponin levels was calculated using
Spearman nonparametric correlation. Group comparisons
of all continuous variables were calculated using Mann-
Whitney statistics. Survival curves were prepared according
to the method of Kaplan-Meier (19), and univariate survival
distribution was compared by the log-rank test. Two-sided
p values0.05 were considered to be statistically significant.
Statistical calculations were performed using the statistical
package StatView, version 4.0 (SAS Institute Inc., Cary,
North Carolina).
RESULTS
Patient characteristics. The baseline clinical characteris-
tics of the study population are presented in Table 1.
Twenty-seven patients (47%) had sepsis or systemic inflam-
matory response syndrome, and six of them were aplastic
due to chemotherapy of hematologic malignancies. Septic
shock requiring supportive therapy with catecholamines was
diagnosed in 24 patients (41%), and 4 of them were aplastic.
The remaining seven patients (12%) were hospitalized due
to a variety of conditions, such as intoxication, gastrointes-
tinal bleeding, pulmonary disease, and diabetic coma. The
severity of diseases was indicated by a high mean SAPS of
42 points at study inclusion. A causative microbial agent
could be isolated in 38 (75%) of 51 patients with sepsis or
septic shock. Gram-positive bacterial infection was found in
15 patients, gram-negative infection in 19, and mixed or
fungal/viral infection in 4 patients. Eleven (73%) of 15
patients with gram-positive infection and 11 (58%) of 19
patients with gram-negative infection were troponin-
positive.
Troponin status and mortality. Thirty-two (55%) of all 58
study patients, or 32 (63%) of 51 patients admitted for
sepsis, SIRS, or septic shock, were troponin-positive. The
majority of troponin-positive patients (72%) were positive
for cTnT and cTnI. The remaining patients were positive
for either cTnT or cTnI (Table 1). Seventeen (71%) of 24
patients with shock were troponin-positive, compared with
15 (44%) of 34 patients without shock (p  0.04). The
SAPS (43  17 vs. 42  12; p  0.74) and age (59  21
vs. 50  19; p  0.08) did not differ significantly between
troponin-positive and -negative patients.
Thirty days after study inclusion, mortality was assessed
in all patients according to their cardiac troponin status (Fig.
1A). A total of 16 patients (27.6%) had died. Mortality of
troponin-positive patients was significantly higher than that
of troponin-negative patients (p  0.018). The hazard ratio
to die from any cause was 4.0 (95% confidence interval 1.2
to 8.9) for troponin-positive patients. When subgroups were
analyzed according to their hemodynamic status (“shock” vs.
“no shock”), a significantly higher mortality (p  0.03) was
found only in troponin-positive patients without shock, but
not in those with volume-refractory shock receiving cate-
cholamine therapy (Fig. 1B).
Cardiac involvement. Among the 32 troponin-positive
patients, significant flow-limiting coronary artery disease
could be excluded by dobutamine stress echocardiography
after recovery from disease in 16 patients, by coronary
angiography in one patient, and by autopsy in six cases
(Table 2). In one patient, subacute myocardial infarction (n
 1) and high-grade coronary artery stenosis with individ-
ual cardiomyocyte necroses (n  1) could be demonstrated
at autopsy. One coronary angiogram and one stress echo-
cardiogram showed evidence of an old myocardial scar, but
no signs of actual ischemia. In summary, flow-limiting
coronary artery disease was not demonstrable in 72% of
troponin-positive patients. We found a significantly lower
LVEF in cardiac troponin-positive as compared with
troponin-negative patients (48  13% vs. 60  10%; p 
Figure 1. Kaplan-Meier survival analysis of troponin-positive and
-negative patients. (A) The overall 30-day mortality was significantly
higher in troponin-positive (n  32) than in troponin-negative (n  26)
patients (p  0.018). (B) When subgroups of patients with volume-
refractory shock needing catecholamine therapy (n  24) and patients
without shock (n  34) were analyzed separately, a significant difference in
mortality was found in the subgroup without shock only (p  0.03). ns 
not significant.
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0.0006). All patients with LVEF below 45% had sepsis or
septic shock and were either cTnI- or cTnT-positive. In
contrast, only 19 (42%) of 45 patients with LVEF 45%
were troponin-positive. A statistically significant inverse
correlation between cTnI levels and LVEF was found, with
a relatively low correlation coefficient (r 0.44, p 0.0006)
(Fig. 2).
Cytokine levels. The median cytokine levels in cardiac
troponin-positive and -negative patients are presented in
Table 3. Troponin-positive patients showed significantly
higher levels of TNF-alpha (p  0.0007), its soluble
receptor (p  0.0001), IL-6 (p  0.0007), and C-reactive
protein (p  0.0002). In contrast, there was no difference in
the median levels of IL-1-beta (p  0.11), IL-8 (p  0.26),
and soluble intercellular adhesion molecule-1 (p  0.07).
Subgroup analyses revealed that the observed median cyto-
kine level difference between troponin-positive and
-negative patients was mainly generated by the subgroup of
patients without volume-refractory shock. Significantly
higher levels of TNF-alpha, its soluble receptor, IL-6, and
C-reactive protein for troponin-positive compared with
troponin-negative patients were found in the subgroup with
sepsis or SIRS, but not in those patients with volume-
refractory septic shock (Table 3).
Role of neutrophilic granulocytes. All 10 aplastic patients
with sepsis or septic shock were troponin-negative at the
time of study entrance. Three of them became troponin-
positive shortly after leukocyte recovery and subsequently
died. In contrast, all others remained troponin-negative and
survived.
DISCUSSION
In the present study, 32 (55%) of 58 critically ill patients
consecutively admitted to two medical intensive care units
due to severe illnesses other than ACS, or 32 (63%) of 51
patients admitted for sepsis, SIRS, or septic shock, were
troponin-positive. Mortality was fourfold higher and LVEF
significantly lower in troponin-positive patients as com-
pared with troponin-negative patients. To our knowledge,
this is the first study that attempted to systematically
exclude significant coronary artery disease by autopsy or
stress echocardiography in the majority of troponin-positive
patients. Remote stress echocardiography cannot defini-
tively exclude microembolism from non–flow-limiting un-
stable plaques as a cause for elevated troponins. However,
ethical considerations did not allow us to perform coronary
angiography in every one of these severely ill patients to
check this hypothesis for troponin release. Our data indicate
that troponin elevation may be used as a new mortality risk
factor for intensive care patients without coronary artery
disease. It is noteworthy that there was no significant
difference in the SAPS between troponin-positive and
-negative patients, although a significantly higher percent-
age of patients presenting with shock, compared with those
without shock, were troponin-positive. This was surprising.
According to our results, troponin in intensive care patients
gives additional prognostic information beyond conven-
tional risk scoring.
In troponin-positive patients, the median levels of TNF-
alpha, its soluble receptor, and IL-6 levels were significantly
higher than those of troponin-negative patients. These
findings suggest but cannot prove, due to the observational
study design, that myocardial depression with elevation of
cardiac troponins might be mediated by TNF-alpha. This
hypothesis is supported by in vitro studies showing that
Table 2. Screening of Troponin-Positive Patients for Coronary
Artery Disease*
Survivors
(n  19)
Deaths
(n  13)
Total
(n  32)
Tests performed 17 (89%) 8 (62%) 25 (78%)
Test results
Normal 15 6 21
Pathologic 2† 2‡ 4
Relevant coronary artery disease
Negative 17 (89%) 6 (46%) 23 (72%)
Positive 0 2 (15%) 2 (6%)
Patient not tested§ 2 (11%) 5 (38%) 7 (22%)
*Troponin-positive surviving patients were tested by dobutamine stress echocardiog-
raphy within three months after hospital discharge (n  16) or by coronary
angiography during hospitalization (n  1). Troponin-positive patients who died
were autopsied. †One patient had an inferior myocardial scar on the electrocardio-
gram and a corresponding occlusion of the right coronary artery on the coronary
angiogram; one patient showed a myocardial scar on stress echocardiography. Because
these two patients had no signs of active myocardial ischemia, they were classified as
negative for relevant ischemic heart disease in the final analysis. ‡One patient had
high-grade stenosis of the left circumflex artery and subacute myocardial infarction;
one patient showed stenosing coronary artery disease and individual cardiomyocyte
necrosis. §Stress echocardiography could not be performed in two patients because of
their personal refusal. Autopsy could not be performed in five patients because of
refusal by their relatives. Data represented as the number (%) of patients.
Figure 2. Relationship between left ventricular ejection fraction (LVEF)
and peak cardiac troponin I (cTnI) level. A significantly lower LVEF was
found in troponin-positive versus -negative patients (r  0.44, p 
0.0006). All patients with LVEF 45% (left of thin vertical line) had
sepsis or septic shock, and 11 of 13 were troponin-positive. The normal
cutoff level for cTnI is indicated at 0.1 g/l by a bold horizontal line.
2007JACC Vol. 41, No. 11, 2003 Ammann et al.
June 4, 2003:2004–9 Troponin in Critically Ill Patients
TNF-alpha leads to reduced contractility of cardiomyocytes
(20). Although clinical trials with anti-TNF antibodies or
p55 TNF receptor fusion protein in patients with severe
sepsis failed to improve survival (21–23), this does not
exclude that elevated TNF-alpha blood levels may cause
myocardial damage and hence contribute to the poor sur-
vival in these patients. However, as suggested in a previous
review (24), our results also indicate that neither the
systemic inflammatory response to sepsis nor troponin
positivity is sufficient to explain circulatory shock in patients
with severe sepsis.
Ten of our patients developed sepsis or septic shock while
they had aplasia. At recruitment, all were troponin-negative.
During leukocyte recovery, three of them became troponin-
positive and subsequently died, whereas all the others stayed
troponin-negative and survived. This observation suggests
that, in addition to TNF-alpha, mediators produced by
young and highly activated neutrophilic granulocytes may
cause troponin elevation in patients with sepsis or septic
shock. In healthy volunteers, it has been reported that
pretreatment with granulocyte colony-stimulating factor
considerably increased the plasma levels of TNF-alpha, its
soluble receptor, and IL-6 on administration of endotoxin
(25). Further studies are warranted to confirm this new
possible interaction between young highly active granulo-
cytes and myocardial damage in a larger patient population.
These findings might be relevant for all septic patients
receiving granulocyte colony-stimulating factor during apla-
sia.
Based on the findings of Piper et al. (26), who showed
cardiac enzyme release without cell necrosis after reversible
ischemia in vitro, we speculate that TNF-alpha and medi-
ators produced by neutrophilic granulocytes may lead to an
increased permeability of the cardiomyocyte membrane for
macromolecules and therefore leakage of troponin without
myocyte necrosis (10).
Conclusions. We found a significantly higher mortality of
cardiac troponin-positive patients admitted to medical in-
tensive care units for reasons other than ACS. Our data
show an association between troponin positivity and TNF-
alpha, IL-6, and left ventricular dysfunction. Further studies
in larger patient populations must establish whether ele-
vated troponin may be used as an independent mortality risk
factor for intensive care patients without ACS.
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